TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16191068

Group type: EXPERIMENTAL
Intervention: 1-hour alteplase (TPA) dwell
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: > 48-hour alteplase (TPA) dwell
Number of subjects: 60
Study: 12972682

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 21
Study: 11063377

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 0
Study: 8804944

Group type: EXPERIMENTAL
Intervention: NIVS with BiPAP (bilevel positive airway pressure) for 3 days (two daytime sessions of 3 hours each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (standard treatment with oxygen, bronchodilators, and steroids)
Number of subjects: 24
Study: 1998858

Group type: EXPERIMENTAL
Intervention: Healthy volunteers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with diarrhoea
Number of subjects: 48

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Other symptomatic patients
Number of subjects: 48
Study: 6395281

Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 76
Study: 31859226

Group type: EXPERIMENTAL
Intervention: Video Coaching (VC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional Teaching (CT)
Number of subjects: 16
Study: 31583947

Group type: EXPERIMENTAL
Intervention: Ad containing 2 benefit outcomes and multiple risk categories
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Ad containing a single benefit outcome
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Ad containing multiple risk categories
Number of subjects: 945

Group type: COMPARATOR
Intervention: Ad containing a single risk category
Number of subjects: 945
Study: 28245227

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified yoghurt (MNFY) with behavior change communication (BCC) campaign
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group receiving BCC only
Number of subjects: 449
Study: 23800099

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified wheat flour chapatti
Number of subjects: 352

Group type: COMPARATOR
Intervention: Wheat flour without added micronutrients (control)
Number of subjects: 352
Study: 24921439

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with Social Evaluation (CPT with SE)
Number of subjects: 59
Study: 22411774

Group type: EXPERIMENTAL
Intervention: Training group using orthographically biased stimuli and principles of motor learning (PML)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 14
Study: 19327952

Group type: EXPERIMENTAL
Intervention: Sequential Compression Devices (SCDs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Venous Foot Pumps (VFPs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) admission
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall compliance score
Number of subjects: 150
Study: 18096809

Group type: EXPERIMENTAL
Intervention: Placement in foster care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued institutional care
Number of subjects: 0
Study: 16169399

Group type: EXPERIMENTAL
Intervention: 100 IU of recombinant human FSH on alternate days for 3 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonresponder group
Number of subjects: 112
Study: 12891533

Group type: EXPERIMENTAL
Intervention: Daily lysine acetylsalicylate (aspirin) 160 or 300 mg/day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 10554941

Group type: EXPERIMENTAL
Intervention: Usual antenatal care plus smoking cessation intervention
Number of subjects: 732
Study: 8678279

Group type: EXPERIMENTAL
Intervention: 700 mg mepivacaine without epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 700 mg mepivacaine with 0.2 mg epinephrine (1:350,000)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 700 mg prilocaine 1%
Number of subjects: 60
Study: 1909693

Group type: EXPERIMENTAL
Intervention: Resorbable sutures (polydioxanone, PDS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Non-resorbable sutures (polyamide, Ethilon)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 425
Study: 6130330

Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31799473

Group type: EXPERIMENTAL
Intervention: Year 1 recruitment methods
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Year 2 recruitment methods
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Average cost for retained participants in Year 1
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Average cost for retained participants in Year 2
Number of subjects: 187
Study: 30403521

Group type: EXPERIMENTAL
Intervention: NET-Works intervention
Number of subjects: 534
Study: 26400955

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) group performing an injury prevention programme as a warm-up 3 times weekly for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CON) completing regular warm-up exercise programme
Number of subjects: 40
Study: 24611849

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 105
Study: 22495703

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (completion of three to four cycles)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (completion of one to two cycles)
Number of subjects: 130
Study: 20002660

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 30
Study: 17668348

Group type: EXPERIMENTAL
Intervention: Cocaethylene infusion at 200 ng/mL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaethylene infusion at 50 ng/mL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cocaethylene infusion at 0 ng/mL (placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine injection (0.5 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine injection (0.25 mg/kg)
Number of subjects: 8
Study: 16274485

Group type: EXPERIMENTAL
Intervention: Surfactant function assessment (minimal surface tension)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lung function assessment (FEV1, MEF(75/25%VC), MEF(25%VC))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surfactant specific proteins A, C, and D
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surfactant protein B (SP-B)
Number of subjects: 20
Study: 12360545

Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa and bromocriptine
Number of subjects: 31

Group type: COMPARATOR
Intervention: selegiline
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 10192753

Group type: EXPERIMENTAL
Intervention: PPS i.v. (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PPS orally (1500 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (orally)
Number of subjects: 18
Study: 7479627

Group type: EXPERIMENTAL
Intervention: 800-kcal weight-loss program for 12 weeks
Number of subjects: 40
Study: 2097905

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 32

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 32
Study: 393788

Group type: EXPERIMENTAL
Intervention: Butorphanol/acetaminophen (4 mg/650 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butorphanol/acetaminophen (2 mg/325 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31620939

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (2 lozenges/day after brushing for 3 months with a 3-month washout)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29380388

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 50
Study: 28317075

Group type: EXPERIMENTAL
Intervention: Police-school partnership intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25741444

Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 454

Group type: COMPARATOR
Intervention: Nonobese individuals
Number of subjects: 454
Study: 23971720

Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day for 3 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day after washout
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract
Number of subjects: 102
Study: 20939862

Group type: EXPERIMENTAL
Intervention: Pelvicol(TM)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: TVT(TM)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Autologous fascial slings (AFS)
Number of subjects: 201
Study: 19133084

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 5% w/v povidone iodine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl followed by sodium ascorbate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no disinfectant)
Number of subjects: 116
Study: 16179098

Group type: EXPERIMENTAL
Intervention: Carboplatin/vinorelbine every 4 weeks as first-line treatment
Number of subjects: 40
Study: 12740739

Group type: COMPARATOR
Intervention: Follicular phase in sedentary women; testosterone glucuronide (TG): 1.67 +/- 0.70 nmol x mmol C -1; epitestosterone glucuronide (ETG): 2.51 +/- 0.88 nmol x mmol C -1; TG/ETG ratio: 0.72 +/- 0.26; cortisol (FLU): 10.02 +/- 0.79 nmol x mmol C -1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follicular phase in trained women; TG: 1.96 +/- 1.00 nmol x mmol C -1; ETG: 1.97 +/- 0.70 nmol x mmol C -1; TG/ETG ratio: 0.66 +/- 0.05; FLU: 11.31 +/- 3.73 nmol x mmol C -1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luteal phase in trained women; TG: 1.93 +/- 0.86 nmol x mmol C -1; ETG: 3.19 +/- 1.23 nmol x mmol C -1; TG/ETG ratio: 0.69 +/- 0.33; FLU: 9.52 +/- 3.86 nmol x mmol C -1
Number of subjects: 0
Study: 10788032

Group type: EXPERIMENTAL
Intervention: Quality system intervention (identification of barriers, documentation, education, feedback, and peer review)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quality system intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 19
Study: 8865683

Group type: EXPERIMENTAL
Intervention: Direct percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 1741115

Group type: EXPERIMENTAL
Intervention: Tight patching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Light patching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline controls (contralateral eye)
Number of subjects: 30
Study: 6510544

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional insulin injections
Number of subjects: 25
Study: 30825465

Group type: EXPERIMENTAL
Intervention: Peanut avoidance group (carriers of the MALT1 locus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peanut avoidance group (non-carriers of the MALT1 locus)
Number of subjects: 0
Study: 29386156

Group type: EXPERIMENTAL
Intervention: Malarina
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine Bisulphate
Number of subjects: 100
Study: 27154476

Group type: EXPERIMENTAL
Intervention: Implementation of the 7 steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 5094
Study: 24094476

Group type: EXPERIMENTAL
Intervention: CricKey surgical cricothyroidotomy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open surgical cricothyroidotomy
Number of subjects: 15
Study: 22021371

Group type: EXPERIMENTAL
Intervention: Thalidomide maintenance
Number of subjects: 820

Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 820
Study: 21246848

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Tuina
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nobex (intramuscular injection)
Number of subjects: 40
Study: 18261664

Group type: EXPERIMENTAL
Intervention: Hylan injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study: 15722306

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's block (STB) with 3 ml of 2% lidocaine and hyaluronidase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Topical anaesthesia (TOP) with proxymetacaine 0.5% and amethocaine 1% eye drops
Number of subjects: 28
Study: 12651660

Group type: EXPERIMENTAL
Intervention: Anesthetic Conserving Device (ACD) at 8 L/min FGF
Number of subjects: 81

Group type: COMPARATOR
Intervention: Circle system with 1‐, 1.5‐, 3‐, and 6‐L/min FGFs
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Anesthetic Conserving Device (ACD)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low‐flow circle system (1.5‐ and 1‐L/min FGFs)
Number of subjects: 81
Study: 11903523

Group type: COMPARATOR
Intervention: Butalbital-containing analgesics
Number of subjects: 0
Study: 9215287

Group type: EXPERIMENTAL
Intervention: tiratricol (24 micrograms/kg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: L‐T4 (1.9 micrograms/kg daily)
Number of subjects: 24
Study: 8434309

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Chemonucleolysis
Number of subjects: 141
Study: 3315270

Group type: EXPERIMENTAL
Intervention: 0800 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2000 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0800 hr and 2000 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8
Study: 31309355

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 62
Study: 29244542

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 26
Study: 28125763

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 25823561

Group type: EXPERIMENTAL
Intervention: Exercise program with health counselling for four weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (routine clinical practice)
Number of subjects: 96
Study: 24119474

Group type: EXPERIMENTAL
Intervention: Arthroscopic transcapsular iliopsoas tenotomy from the peripheral compartment (Group 1, n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Arthroscopic transcapsular iliopsoas tenotomy from the central compartment (Group 2, n=9)
Number of subjects: 19
Study: 22092475

Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip (CHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flurbiprofen chip (FBP)
Number of subjects: 60
Study: 19747069

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxybutynin IR 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17014663

Group type: EXPERIMENTAL
Intervention: 3% zinc oxide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15116142

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 11110737

Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Galantamine (32 mg)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study: 9308074

Group type: EXPERIMENTAL
Intervention: Mianserin (maximum daily dose 90 mg) and Carbamazepine (maximum daily dose 400 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clonidine (maximum daily dose 0.600 mg)
Number of subjects: 32
Study: 8334029

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) (0.25-0.50 microgram/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxy vitamin D3 (24,25(OH)2D3) (daily dose of 15 micrograms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of 1,25(OH)2D3 and 24,25(OH)2D3
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcium carbonate (maximal dosage of 1 g x 3)
Number of subjects: 24
Study: 31078475

Group type: EXPERIMENTAL
Intervention: Financial incentives on an escalating schedule ($4 to $50) for completing CR sessions
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Patients who completed ≥30 sessions
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Incentive condition group
Number of subjects: 130
Study: 29735458

Group type: EXPERIMENTAL
Intervention: Glimepiride and Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride and Acarbose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride and Rosiglitazone
Number of subjects: 0
Study: 26367325

Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy (4 weekly exercise sessions, 1 weekly group therapy session, 1 weekly nutritional education session)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 24425846

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: No PRP gel (Control)
Number of subjects: 20
Study: 22682911

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (institutional care)
Number of subjects: 0
Study: 20716104

Group type: EXPERIMENTAL
Intervention: 3-D presentation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3-Dc presentation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3-D and 3-Dc modalities
Number of subjects: 160

Group type: COMPARATOR
Intervention: 2-D group
Number of subjects: 160
Study: 17606861

Group type: EXPERIMENTAL
Intervention: >or=75% of visits with BP control
Number of subjects: 22576

Group type: COMPARATOR
Intervention: <25% of visits with BP control
Number of subjects: 22576
Study: 16091270

Group type: EXPERIMENTAL
Intervention: Famous faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfamiliar faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response latency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual field
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explicit familiarity decision
Number of subjects: 0
Study: 12368690

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/dose x2
Number of subjects: 77

Group type: COMPARATOR
Intervention: Methylprednisolone 30 mg/kg/dose x3
Number of subjects: 77
Study: 10192750

Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg once daily for 1 week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8868205

Group type: EXPERIMENTAL
Intervention: Fluoxetine and naltrexone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo and naltrexone
Number of subjects: 98
Study: 2182945

Group type: COMPARATOR
Intervention: Diethylstilbestrol diphosphate (DES‐DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES‐DP) plus vindesine (VND) 3 mg/m2 intravenously on days 8, 15, and 22 (group B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DES‐DP + VND
Number of subjects: 51
Study: 232017

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 0
Study: 30058344

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 29504499

Group type: EXPERIMENTAL
Intervention: Quadrupling inhaled glucocorticoids (increase by a factor of 4)
Number of subjects: 1871

Group type: COMPARATOR
Intervention: Non-quadrupling group (same self-management plan without dose increase)
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Quadrupling inhaled glucocorticoids
Number of subjects: 1871

Group type: COMPARATOR
Intervention: Non-quadrupling group
Number of subjects: 1871
Study: 27041524

Group type: EXPERIMENTAL
Intervention: Synbiotics supplementation for 28 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo capsule for 28 weeks
Number of subjects: 42
Study: 24450858

Group type: EXPERIMENTAL
Intervention: Idelalisib, 150 mg twice daily
Number of subjects: 125
Study: 21671413

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-intensity range of movement exercise (control)
Number of subjects: 18